New products, stock market listing, a US acquisition, a full product suite and forthcoming randomised trial results….Volpara has been very active since we wrote about them in our September 2018 newsletter.
CEO Ralph Highnam dashed out of an investor conference in Australia to give us an update.
“We have new AI breast cancer products, we raised AUD$55million, and we bought an outstanding breast cancer screening company in Seattle,” he says.
“There’s huge interest in improving healthcare globally, with AI being a strong part of that, and investors are willing to put money into this space. Our June 2019 capital raise was fully subscribed which is due to the success we’re having in the US, and the belief that AI, backed up by real science, really can revolutionize how breast cancer screening operates.”
When it came to breaking into the critical US market, Volpara took a proactive approach by purchasing an existing company. “That gave us a critical, additional 20 percent share of the giant US market, meaning one in four US women are now screened using Volpara’s software.”
In the past year, Volpara has developed its product suite and now offers what Ralph describes as a one-stop shop for breast imaging software, with new products and access to global datasets that will potentially predict breast cancer much earlier than is currently possible being the aim as the company strives to save families from breast cancer.
An important part of that is clinical trials and working with academics globally, and Ralph is looking forward to a 10-year Netherlands randomised trial reporting first results soon, with Volpara software helping identify women with extremely dense breast tissues for additional imaging.
“It’s these kinds of trials that are essential for helping population-based screening programmes such as in NZ understand what is possible, and we want to help women locally”.